AI spots pneumonia in chest x-rays of COVID-19 patients

Researchers have developed an AI algorithm that can scan the chest x-rays of COVID-19 patients for signs of pneumonia. In one instant, it even detected the virus in an asymptomatic patient who was getting the chest x-ray for reasons completely unrelated to COVID-19.

“We would not have had reason to treat that patient as a suspected COVID-19 case or test for it, if it weren’t for the AI,” Christopher Longhurst, MD, UC San Diego Health’s chief information officer and associate chief medical officer, said in a statement. “While still investigational, the system is already affecting clinical management of patients.”

Radiologists at UC San Diego Health fist developed the AI model in 2019, hoping it could lead to improvements in the detection of pneumonia. The algorithm was trained with total of 22,000 notations.

“Pneumonia can be subtle, especially if it’s not your average bacterial pneumonia, and if we could identify those patients early, before you can even detect it with a stethoscope, we might be better positioned to treat those at highest risk for severe disease and death,” Albert Hsiao, MD, PhD, a radiologist at UC San Diego Health, said in the same statement.

Hsiao’s team quickly realized that their model could be used to improve care for COVID-19 patients—and it is now being put to the test in a clinical research study funded by Amazon Web Services.

“As an academic medical center, we’re always looking for ways to bring innovations to the bedside,” Longhurst said in the same statement. “Although we need more studies to evaluate the effectiveness of this algorithm and improve its accuracy as we see more patients, what we’re seeing so far is evidence that this approach could be a powerful tool for health care providers to provide more reliable, early diagnoses of COVID-19 and other infections.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.